Flow Pharma, based in East Palo Alto, California, is dedicated to advancing immunotherapy through its T-Cell based vaccine delivery platform. The company focuses on developing vaccines for HIV, Ebola, Marburg, and triple-negative breast cancer. Their technology has shown promising results in both animal studies and human blood tests. Flow Pharma's mission is to transform the treatment and prevention of cancer and viral diseases through innovative immunotherapy solutions.
Flow Pharma has achieved significant milestones, including the first breast cancer collaboration agreement with the largest cancer hospital in Saudi Arabia. Their HIV vaccine application, developed in partnership with Until There’s A Cure, has demonstrated encouraging outcomes. The company continues to expand its impact by leveraging its exclusive technology and manufacturing expertise to address critical health challenges globally.
